Amevive
Amevive Uses, Dosage, Side Effects, Food Interaction and all others data.
Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD.
Interferes with lymphocyte activation by specifically binding to the lymphocyte antigen, CD2, and inhibiting LFA-3/CD2 interaction. Activation of T lymphocytes involving the interaction between LFA-3 on antigen-presenting cells and CD2 on T lymphocytes plays a role in the pathophysiology of chronic plaque psoriasis. Also causes a reduction in subsets of CD2+ T lymphocytes as well as CD4+ and CD8+ T lymphocytes.
Trade Name | Amevive |
Availability | Discontinued |
Generic | Alefacept |
Alefacept Other Names | Alefacept |
Related Drugs | Humira, Otezla, Cosentyx, methotrexate, Enbrel, Remicade, Stelara, cyclosporine, infliximab |
Type | Intramuscular |
Formula | C2306H3594N610O694S26 |
Weight | 51801.1 Da |
Groups | Approved, Investigational, Withdrawn |
Therapeutic Class | |
Manufacturer | |
Available Country | United States |
Last Updated: | September 19, 2023 at 7:00 am |
Uses
Amevive is a recombinant fusion protein that binds CD2 and is used treat moderate to severe plaque psoriasis.
As an immunosuppressive drug, Amevive can be used for treatment of moderate to severe chronic plaque psoriasis
How Amevive works
Inhibits T-lymphocyte activation and production by binding to the CD2 lymphocyte antigen.
Toxicity
While it has been found to cross the placenta in monkeys, it is not yet known if it also diffuses into breast milk.
Elimination Route
Bioavailability after IM administration is 63%.
Half Life
~270 hours
Innovators Monograph
You find simplified version here Amevive